It remains difficult to reconcile the therapeutic effect of α4β7-MAdCAM-1 blockade seen in patients treated with VDZ or ontamalimab (anti-MAdCAM-1) with the hastening effect of a parallel intervention on IL-10−/− colitis. Here, MADCAM1 is linked to colitis.